These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37902266)

  • 1. Comparative analysis of clinicopathologic characteristics and prognosis between nasal and nonnasal extranodal NK/T-cell lymphoma.
    Shen Z; Chen X; Sun C; Lu T; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Zhang X; Wang L; Cai G; Sang W
    Cancer Med; 2023 Dec; 12(23):21138-21147. PubMed ID: 37902266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
    Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
    [No Abstract]   [Full Text] [Related]  

  • 4. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
    Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
    Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of prognostic nutritional index on extranodal natural killer/T-cell lymphoma patients: A multicenter propensity score matched analysis of 1022 cases in Huaihai Lymphoma Working Group.
    Shen Z; Zhang S; Chen X; Zhang Q; Jiao Y; Shi Y; Zhang H; Ye J; Wang L; Zhu T; Miao Y; Wang L; Cai G; Sang W
    Hematol Oncol; 2023 Aug; 41(3):380-388. PubMed ID: 36680513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel prognostic index for extranodal natural killer/T-cell lymphoma in the era of pegaspargase/L-asparaginase.
    Shen Z; Zhang X; Li Y; Chen X; Xing X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Liu H; Wang L; Sang W
    Future Oncol; 2024; 20(28):2071-2081. PubMed ID: 39041580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, prognostic stratification, and treatment of advanced-stage non-nasal type extranodal natural killer/T-cell lymphoma: a multi-institutional real-world study.
    Wei YC; Liu WX; Qi F; Zhang CG; Zheng BM; Xie Y; Chen B; Zhang D; Liu WP; Fang H; Chai Y; Qi SN; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Ann Hematol; 2024 Jan; 103(1):163-174. PubMed ID: 37817010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A five
    Vittayawacharin P; Khuhapinant A
    Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
    Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
    Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and Prognosis of Newly Diagnosed Advanced-Stage Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Real-World Study across Two Decades.
    Wei YC; Qi F; Chen B; Zhang CG; Fang H; Zhang D; Qi SN; Chai Y; Li YX; Dong M
    Chemotherapy; 2024; 69(2):108-121. PubMed ID: 37984344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased body mass index is associated with improved overall survival in extranodal natural killer/T-cell lymphoma, nasal type.
    Li YJ; Yi PY; Li JW; Liu XL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Yao Y; Fan Z; Tang T; Jiang WQ
    Oncotarget; 2017 Jan; 8(3):4245-4256. PubMed ID: 28002803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
    Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
    Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yong W
    Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase.
    Yang J; Li P; Piao Y; Liu X; Wei L; Sang W; Zhang L; Wang L
    Front Immunol; 2022; 13():829366. PubMed ID: 35371002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extranodal natural killer/T-Cell lymphoma: A population-based comparison of sinonasal and extranasal disease.
    Vazquez A; Khan MN; Blake DM; Sanghvi S; Baredes S; Eloy JA
    Laryngoscope; 2014 Apr; 124(4):888-95. PubMed ID: 24114591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.